VX 210

Drug Profile

VX 210

Alternative Names: BA-210; Cethrin; VX-210

Latest Information Update: 04 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator BioAxone Therapeutic
  • Developer BioAxone Biosciences; Vertex Pharmaceuticals
  • Class Neuroprotectants; Recombinant fusion proteins
  • Mechanism of Action Rho GTP-binding protein-inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Spinal cord injuries
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Spinal cord injuries
  • No development reported Age-related macular degeneration; Glaucoma; Optic nerve disorders

Most Recent Events

  • 23 Feb 2017 Vertex Pharmaceuticals has patent protection for BA 210 in USA and countries outside USA (Vertex Pharmaceuticals form 10-K, filed in February 2017)
  • 01 Feb 2016 Phase-II/III clinical trials in Spinal cord injuries (In adolescents, In adults) in USA (Epidural) (NCT02669849)
  • 17 Aug 2015 Phase-II development is ongoing for Spinal cord injuries in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top